Myriad Genetics (MYGN) CTO has shares withheld to cover taxes

Rhea-AI Filing Summary

MYRIAD GENETICS INC Chief Technology Officer Kevin Richard Haas reported share dispositions that were entirely for tax withholding. Over March 13–15, 2026, a total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units.

These F-code transactions are not open-market sales and do not reflect discretionary selling activity. After these tax-withholding events, Haas continues to hold 180,022 shares of Common Stock directly.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Haas Kevin Richard

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	3,355	$4.66	$16K
Tax Withholding	Common Stock	8,382	$4.66	$39K
Tax Withholding	Common Stock	4,161	$4.66	$19K
Tax Withholding	Common Stock	6,412	$4.66	$30K

Holdings After Transaction: Common Stock — 188,404 shares (Direct)

Footnotes (1)

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haas Kevin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		F		6,412(1)	D	$4.66	195,920	D
Common Stock	03/14/2026		F		4,161(1)	D	$4.66	191,759	D
Common Stock	03/15/2026		F		3,355(1)	D	$4.66	188,404	D
Common Stock	03/15/2026		F		8,382(2)	D	$4.66	180,022	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Remarks:

The Reporting Person is no longer serving in the role of Chief Technology Officer of Myriad Genetics, Inc., effective March 16, 2026, and therefore is no longer subject to Section 16 reporting.

	By: Justin Hunter For: Kevin Richard Haas	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MYGN CTO Kevin Haas report in this Form 4 filing?

Kevin Haas reported tax-related share dispositions only. A total of 22,310 Myriad Genetics Common Stock shares were withheld by the company to cover tax obligations arising from the vesting of restricted and performance-based stock units.

How many MYGN shares were withheld for Kevin Haas’s tax obligations?

A total of 22,310 shares of Myriad Genetics Common Stock were withheld. These shares covered tax liabilities associated with vesting restricted stock units and performance-based restricted stock units previously granted to Kevin Haas as part of his compensation.

Do Kevin Haas’s MYGN Form 4 transactions represent open-market sales?

No, the transactions do not represent open-market sales. All reported entries use code F, meaning shares were withheld by Myriad Genetics solely to satisfy tax withholding obligations tied to vesting equity awards, rather than discretionary selling in the market.

How many MYGN shares does Kevin Haas hold after these tax withholdings?

Following the reported tax-withholding dispositions, Kevin Haas directly holds 180,022 shares of Myriad Genetics Common Stock. This post-transaction figure shows he retains a substantial equity position in the company despite the shares withheld for tax obligations.

What price was used to determine MYGN shares withheld for Kevin Haas’s taxes?

The number of shares withheld was based on the closing price of Myriad Genetics Common Stock on March 13, 2026. Transactions in the filing reflect a price of $4.66 per share for calculating the share amount needed to satisfy tax obligations.